|Dr. Philip Frost||Chairman and Chief Exec. Officer||970.6k||N/A||1936|
|Dr. Jane H. Hsiao Ph.D., MBA||Vice Chairman and Chief Technical Officer||970.6k||N/A||1947|
|Mr. Adam E. Logal||Chief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer||610.6k||N/A||1978|
|Mr. Steven D. Rubin||Exec. VP of Admin. and Director||820.6k||2.29M||1960|
|Ms. Kate Inman Esq.||Deputy Gen. Counsel and Sec.||N/A||N/A||1973|
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
OPKO Health, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 3; Compensation: 7.